A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $11 to $18
Buy Rating on Black Diamond Therapeutics: Promising Phase 2 Results for BDTX-1535 in NSCLC Treatment
Black Diamond Theraptcs Is Maintained at Overweight by Piper Sandler
Black Diamond Therapeutic Analyst Ratings
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11
Buy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment Advances
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $12
Black Diamond Therapeutic Analyst Ratings
Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $16
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $12
Black Diamond Therapeutics (BDTX) Gets a Buy From Piper Sandler
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11
Wedbush Reiterates Outperform on Black Diamond Therapeutic, Maintains $16 Price Target
Black Diamond Therapeutic Analyst Ratings
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating
Buy Rating on Black Diamond Therapeutics: Promising Early Results for BDTX-1535 in NSCLC Treatment
Black Diamond Therapeutic Analyst Ratings
Raymond James Initiates Black Diamond Therapeutics(BDTX.US) With Buy Rating, Announces Target Price $20
Black Diamond Therapeutic Analyst Ratings